EGFR and non-small cell lung carcinoma: In addition to the data based on 61 matched pre/post-osimertinib cfDNA in the FLAURA trial, one recent study presented a series of 27 matched pre-post treatment biopsies obtained from patients with EGFR-mutant NSCLC treated with osimertinib in first-line therapy [58,70].